According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to $38.31 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Catalyst Pharmaceuticals is not utilizing their capital as effectively as possible. In Q3, Catalyst Pharmaceuticals earned $10.33 million and total sales reached $35.95 million.
